The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
High neutrophil-to-lymphocyte ratio (NLR), myeloid-derived suppressor cells (MDSCs) and resistance to corticosteroid therapy (CST) in castration-resistant prostate cancer (CRPC).
 
Niven Mehra
No Relationships to Disclose
 
Ricardo Marcelo Morilla
No Relationships to Disclose
 
Adam Sharp
No Relationships to Disclose
 
Alison Morilla
No Relationships to Disclose
 
Mateus Crespo
No Relationships to Disclose
 
Maryou B. Lambros
No Relationships to Disclose
 
Karen Thomas
No Relationships to Disclose
 
Daniel Nava Rodrigues
No Relationships to Disclose
 
Diletta Bianchini
Travel, Accommodations, Expenses - Janssen
 
Penelope Flohr
No Relationships to Disclose
 
David P. Dearnaley
Honoraria - Takeda
Consulting or Advisory Role - Cadence Research and Consulting; FirstWord; Janssen; Janssen Research & Development; Sandoz; Takeda
Expert Testimony - Vitality Life
Travel, Accommodations, Expenses - Takeda
 
Chris C. Parker
Honoraria - Bayer; BN ImmunoTherapeutics; Janssen
Consulting or Advisory Role - Bayer Schering Pharma; BN ImmunoTherapeutics; Janssen
Research Funding - Bayer Schering Pharma (Inst)
Travel, Accommodations, Expenses - Bayer Schering Pharma; Janssen
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; Genentech/Roche; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Genentech/Roche; Sanofi
Research Funding - AstraZeneca (Inst); Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); PARP inhibitors and DNA repair defects (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex